Hyderabad-based pharmaceutical company Bharat Biotech has made an announcement regarding their novel infection vaccine approval from the government. The company on Monday announced that they have become the first company in India to get human trial approval for their vaccination called ‘Covaxin’.
According to the reports, this vaccination has been developed with the joint collaboration of the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV). The company’s spokesperson said that the government has approved them for conducting Phase 1 and Phase 2 human clinical trials after they submitted all the important results generated from preclinical studies demonstrating immunity and safety response.
Talking about when this vaccine will be available in the market, the company’s spokesperson said that it would be difficult to give an exact estimation as the process will take time but once the complete trials are done and reports are approved by the government, they will start mass manufacturing.
When asked about the complete plan, the company said that the first step will be getting started with the Phase 1 trial. And based on the results, the regulatory will decide how many people will be eligible for Phase 2 of the trial. In the end, the company revealed that if everything goes well, it would take around 4-5 months for the complete human trial process.